Related Experiment Video
Updated: Jun 26, 2026
11:39
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Calcineurin Inhibitors in Atopic Dermatitis: Balancing Tradition with Emerging Therapeutics.
Rakesh Kumar1,2, Syed Arman Rabbani3, Mohamed El-Tanani3
1Amity Institute of Pharmacy, Amity University, Gurgaon 122413, Haryana, India.
Medical Sciences (Basel, Switzerland)
|June 25, 2026
Summary
Topical calcineurin inhibitors (CNIs) offer a safe, steroid-sparing option for atopic dermatitis (AD) treatment, particularly in sensitive areas. Evidence supports their continued safety and efficacy, especially for pediatric patients.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Atopic dermatitis (AD) is a prevalent chronic inflammatory skin condition with increasing incidence.
- Corticosteroids are the primary AD treatment but have limitations due to adverse effects.
- Topical calcineurin inhibitors (CNIs) present a steroid-sparing alternative for AD management.
Purpose of the Study:
- To review the role and advancements of topical calcineurin inhibitors (CNIs) in the current atopic dermatitis (AD) treatment paradigm.
- To highlight the safety and efficacy of CNIs as an alternative to corticosteroids.
- To discuss innovations in CNI formulations and delivery systems for AD.
Main Methods:
- Narrative review of existing literature on topical calcineurin inhibitors (CNIs) for atopic dermatitis (AD).
- Analysis of clinical study designs including randomized controlled trials, registry studies, and meta-analyses.
- Examination of safety data, including historical controversies and current evidence.
Main Results:
- CNIs are effective and safe alternatives to corticosteroids, with evidence supporting their use despite past safety concerns.
- CNIs offer a unique therapeutic niche for pediatric patients and sensitive skin areas.
- Innovations in CNI formulations, combination therapies, and delivery systems are expanding their application in precision dermatology.
Conclusions:
- Topical calcineurin inhibitors (CNIs) remain crucial in the atopic dermatitis (AD) treatment landscape, bridging topical corticosteroids and systemic therapies.
- Continued research and innovation in CNI delivery and application are vital for advancing AD management.
- CNIs provide a valuable, localized, and affordable treatment option for various AD presentations.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:27Acne Infection
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
01:25Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...